Markers for addiction

• US 8,080,371 B2
• Filed: 03/01/2007
• Issued: 12/20/2011
• Est. Priority Date: 03/01/2006
• Status: Expired due to Fees

• Current Assignee: Washington University In St Louis
• Original Assignee: Washington University In St Louis
• Inventors: Ballinger, Dennis, Konvicka, Karel, Rice, John, Goate, Alison M., Wang, Jen, Bierut, Laura Jean, Saccone, Frank Scott, Hinrichs, Anthony L.
• Primary Examiner(s): Shaw, Amanda
• Application Number:
  US11/681,177
• Publication Number:
  US 20070258898A1
• Time in Patent Office: 1,755 Days
• Field of Search: None
• US Class Current: 435/6
• CPC Class Codes: A61K 49/0004 Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
• CPC Class Codes: A61P 25/30 for treating abuse or dependence
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/112 Disease subtyping, staging or classification
• CPC Class Codes: C12Q 2600/136 Screening for pharmacological compounds
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers
• CPC Class Codes: C12Q 2600/172 Haplotypes
• CPC Class Codes: G01N 2500/00 Screening for compounds of potential therapeutic value
• CPC Class Codes: G01N 33/5088 of vertebrates
• CPC Class Codes: G01N 33/6893 related to diseases not provided for elsewhere

Abstract

Correlations between polymorphisms and addiction are provided. Methods of diagnosing, prognosing, and treating addiction are provided. Systems and kits for diagnosis, prognosis and treatment of addiction are provided. Methods of identifying addiction modulators are also described.

Claims

1. A method for identifying a human individual with an increased risk for nicotine addiction, the method comprising;

obtaining a biological sample comprising nucleic acid from the human individual, detecting, in the biological sample, the allele present at the rs16969968 polymorphism site on each chromosome, and determining that the human individual has an increased risk for nicotine addiction if the human individual has an A allele present on each chromosome at the rs16969968 polymorphism site compared to a human individual with one A allele or no A alleles at the rs16969968 polymorphism site.

2. The method of claim 1, wherein the detecting comprises amplifying a sequence comprising the allele present at the rs16969968 polymorphism site to generate an amplicon, and detecting the amplicon.

3. The method of claim 2, wherein the amplifying comprises:

I. admixing a primer or a primer pair with a nucleic acid template isolated from the biological sample, wherein the primer or the primer pair is complementary or partially complementary to a region proximal to or including the rs16969968 polymorphism site, and is capable of initiating nucleic acid polymerization by a polymerase on the nucleic acid template; and

,

II. extending the primer or the primer pair in a DNA polymerization reaction comprising a polymerase and the nucleic acid template to generate an amplicon.

4. The method of claim 2, wherein the amplicon is detected by a process that includes one or more of:

hybridizing the amplicon to an array, digesting the amplicon with a restriction enzyme, or real-time PCR analysis.

5. The method of claim 2, comprising partially or fully sequencing the amplicon.

6. The method of claim 2, wherein the amplifying comprises performing a polymerase chain reaction (PCR), reverse transcriptase PCR (RT-PCR), or ligase chain reaction (LCR) using nucleic acid isolated from the biological sample as a template in the PCR, RT-PCR, or LCR.